Pirarubicin inhibits multidrug-resistant osteosarcoma cell proliferation through induction of G 2/M phase cell cycle arrest

Acta Pharmacologica Sinica

Volumn 33, Issue 6, 2012, Pages 832-838

  Zheng, Shui Er ^a   Xiong, Sang ^a   Lin, Feng ^a   Qiao, Guang Lei ^a   Feng, Tao ^a   Shen, Zan ^a   Min, Da Liu ^a   Zhang, Chun Ling ^a   Yao, Yang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Cdc2; Cdc25C; cell cycle; cisplatin; cyclin B1; doxorubicin; G 2 M arrest; gemcitabine; methotrexate; multidrug resistant; osteosarcoma; pirarubicin

Indexed keywords

CISPLATIN; CYCLIN B1; CYCLIN DEPENDENT KINASE 1; DOXORUBICIN; GEMCITABINE; PIRARUBICIN; PROTEIN TYROSINE PHOSPHATASE;

ARTICLE; CELL COUNT; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DEPHOSPHORYLATION; DRUG SENSITIVITY; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; HUMAN; HUMAN CELL; IC 50; MULTIDRUG RESISTANCE; OSTEOSARCOMA CELL; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; CDC2 PROTEIN KINASE; CDC25 PHOSPHATASES; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN B1; DOXORUBICIN; G2 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OSTEOSARCOMA;

EID: 84862540868     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2012.20     Document Type: Article

References (38)

1. Chou AJ, Gorlick R. Chemotherapy resistance in osteosarcoma current challenges and future directions. Expert Rev Anticancer Ther 2006; 6: 1075-85.
2. Hawkins DS, Arndt CA. Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy. Cancer 2003; 98: 2447-56.
3. Chou AJ, Merola PR, Wexler LH, Gorlick RG, Vyas YM, Healey JH, et al. Treatment of osteosarcoma at first recurrence after contemporary therapy: the memorial sloan-kettering cancer center experience. Cancer 2005; 104: 2214-21.
4. Shinozaki T, Watanabe H, Yanagawa T, Shirakura K, Takagishi K. Pirarubicin-based versus doxorubicin-based osteosarcoma chemotherapy. Ann Pharmacother 2002; 36: 996-9.
5. Li JJ, Di GH, Tang LC, Yu KD, Hu Z, Liu GY, et al. Adjuvant therapy of breast cancer with pirarubicin versus epirubicin in combination with cyclophosphamide and 5-fluorouracil. Breast J 2011; 17: 657-60.
6. Kasahara S, Hara T, Tsurumi H, Goto N, Kitagawa J, Kanemura N, et al. Phase II study of the tetrahydropyranyl adriamycin-cyclophosphamide, vincristine, and prednisolone regimen combined with rituximab as first-line treatment for elderly patients with diffuse large B-cell lymphoma. Leuk Lymphoma 2011; 52: 629-34.
7. Kudo K, Kojima S, Tabuchi K, Yabe H, Tawa A, Imaizumi M, et al. Prospective study of a pirarubicin, intermediate-dose cytarabine, and etoposide regimen in children with down syndrome and acute myeloid leukemia: the Japanese Childhood AML Cooperative Study Group. J Clin Oncol 2007; 25: 5442-7.
8. Nagai K, Nagasawa K, Sadzuka Y, Tsujimoto M, Takara K, Ohnishi N, et al. Relationships between the in vitro cytotoxicity and transport characteristics of pirarubicin and doxorubicin in M5076 ovarian sarcoma cells, and comparison with those in Ehrlich ascites carcinoma cells. Cancer Chemother Pharmacol 2002; 49: 244-50.
9. Umezawa H, Takahashi Y, Kinoshita M, Naganawa H, Masuda T, Ishizuka M, et al. Tetrahydropyranyl derivatives of daunomycin and adriamycin. J Antibiot (Tokyo) 1979; 32: 1082-4.
10. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. 4'-O-tetrahydropyranyladr iamycin as a potential new antitumor agent. Cancer Res 1982; 42: 1462-7.
11. Dantchev D, Paintrand M, Hayat M, Bourut C, Mathé G. Low heart and skin toxicity of a tetrahydropyranyl derivate of Adriamycin (THPADM) as observed by electron and light microscopy. J Antibiot (Tokyo) 1979; 32: 1085-6.
12. Zou HY, Wu HL, Zhang Y, Li SF, Nie JF, Fu HY, et al. Studying the interaction of pirarubicin with DNA and determining pirarubicin in human urine samples: combining excitation - emission fluorescence matrices with second-order calibration methods. J Fluoresc 2009; 19: 955-66.
13. Sridhar KS, Hussein AM, Benedetto P, Ardalan B, Savaraj N, Richman SP. Phase II trial of 4'-0-tetrahydropyranyladriamycin (pirarubicin) in head and neck carcinoma. Cancer 1992; 70: 1591-7.
14. Tsurumi H, Hara T, Goto N, Kanemura N, Kasahara S, Sawada M, et al. A phase II study of a THP-COP regimen for the treatment of elderly patients aged 70 years or older with diffuse large B-cell lymphoma. Hematol Oncol 2007; 2: 107-14.
15. Zhao H, Yao Y, Wang Z, Lin F, Sun Y, Yao Y, et al. Therapeutic effect of pirarubicin-based chemotherapy for osteosarcoma patients with lung metastasis. J Chemother 2010; 22: 119-24.
16. Qi WX, He AN, Tang LN, Shen Z, Yao Y. Evaluation of pirarubicincisplatin chemotherapy in the treatment for refractory and recurrent high-grade osteosarcoma: experience of a single institute. Med Oncol 2011. doi: 10.1007/s12032-011-0021-y.
17. Takamoto S, Ota K. Flow cytometric analysis of the effect of THPadriamycin on the cell cycle traverse of RPMI-8402 cells - comparison with adriamycin. Gan To Kagaku Ryoho 1986; 13: 1868-75.
18. Oda Y, Matsumoto Y, Harimaya K, Iwamoto Y, Tsuneyoshi M. Establishment of new multidrug-resistant human osteosarcoma cell lines. Oncol Rep 2000; 7: 859-66.
19. Snow K, Judd W. Characterisation of adriamycin- and amsacrineresistant human leukaemic T cell lines. Br J Cancer 1991; 63: 17-28.
20. Guo JM, Xiao BX, Liu Q, Zhang S, Liu DH, Gong ZH. Anticancer effect of aloe-emodin on cervical cancer cells involves G2/M arrest and induction of differentiation. Acta Pharmacol Sin 2007; 28: 1991-5.
21. Zheng SE, Yao Y, Dong Y, Lin F, Zhao H, Shen Z, et al. Down-regulation of ribosomal protein L7A in human osteosarcoma. J Cancer Res Clin Oncol 2009; 135: 1025-31.
22. Bacci G, Briccoli A, Ferrari S, Longhi A, Mercuri M, Capanna R, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremity: longterm results of the Rizzoli's 4th protocol. Eur J Cancer 2001; 37: 2030-9.
23. Chi SN, Conklin LS, Qin J, Meyers PA, Huvos AG, Healey JH, et al. The patterns of relapse in osteosarcoma: the Memorial Sloan-Kettering experience. Pediatr Blood Cancer 2004; 42: 46-51.
24. Cagliero E, Ferracini R, Morello E, Scotlandi K, Manara MC, Buracco P, et al. Reversal of multidrug-resistance using Valspodar (PSC 833) and doxorubicin in osteosarcoma. Oncol Rep 2004; 12: 1023-31.
25. Serra M, Scotlandi K, Reverter-Branchat G, Ferrari S, Manara MC, Benini S, et al. Value of P-glycoprotein and clinicopathologic factors as the basis for new treatment strategies in high-grade osteosarcoma of the extremities. J Clin Oncol 2003; 21: 536-42.
26. Hornicek FJ, Gebhardt MC, Wolfe MW, Kharrazi FD, Takeshita H, Parekh SG, et al. P-glycoprotein levels predict poor outcome in patients with osteosarcoma. Clin Orthop 2000; 373: 11-7.
27. Kubota T, Furukawa T, Tanino H, Oura S, Murata H, Yuasa S, et al. Pirarubicin might partly circumvent the P-glycoprotein-mediated drug resistance of human breast cancer issues. Anticancer Res 1998; 18: 967-72.
28. Kunimoto S, Miura K, Umezawa K. Cellular uptake and efflux and cytostatic activity of 4'-O-tetrahydropyranyladriamycin in adriamycinsensitive and resistant tumor cell lines. J Antibiot (Tokyo) 1984; 37: 1697-702.
29. Liu SY, Song SX, Lin L, Liu X. Molecular mechanism of cell apoptosis by paclitaxel and pirarubicin in a human osteosarcoma cell line. Chemotherapy 2010; 56: 101-7.
30. Maruyama T, Higuchi Y, Suzuki T, Qiu J, Yamamoto S, Shima H. Double short-time exposure to pirarubicin produces higher cytotoxicity against T24 bladder cancer cells. J Infect Chemother 2011; 17: 11-6.
31. Suryadinata R, Sadowski M, Sarcevic B. Control of cell cycle progression by phosphorylation of cyclin-dependent kinase (CDK) substrates. Biosci Rep 2010; 30: 243-55.
32. Yen CY, Chiu CC, Chang FR, Chen JY, Hwang CC, Hseu YC, et al. 4beta- Hydroxywithanolide E from Physalis peruviana (golden berry) inhibits growth of human lung cancer cells through DNA damage, apoptosis and G2/M arrest. BMC Cancer 2010; 10: 46.
33. Stan SD, Zeng Y, Singh SV. Ayurvedic medicine constituent withaferin a causes G2 and M phase cell cycle arrest in human breast cancer cells. Nutr Cancer 2008; 60: 51-60.
34. Dvory-Sobol H, Cohen-Noyman E, Kazanov D, Figer A, Birkenfeld S, Madar-Shapiro L, et al. Celecoxib leads to G2/M arrest by induction of p21 and down-regulation of cyclin B1 expression in a p53- independent manner. Eur J Cancer 2006; 42: 422-6.
35. Doree M, Hunt T. From Cdc2 to Cdk1: when did the cell cycle kinase join its cyclin partner? J Cell Sci 2002; 115: 2461-4.
36. Taylor WR, Stark GR. Regulation of the G2/M transition by p53. Oncogene 2001; 20: 1803-15.
37. Lopez-Girona A, Furnari B, Mondesert O, Russell P. Nuclear localization of Cdc25 is regulated by DNA damage and a 14-3-3 protein. Nature 1999; 397: 172-5.
38. Sanchez Y, Wong C, Thoma RS, Richman R, Wu Z, Piwnica-Worms H, et al. Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25. Science 1997; 277: 1497-501.